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Dr Robert Cerfolio (Birmingham, Ala). These survival results
are going to be unbelievable to many, especially when you have 27
patients with N3 disease and many with T4 disease. Therefore, can
you tell us how you have such great survival in patients with N3,
how you reassess N3, and are these nodes that are contiguous N3
as opposed to distant N3? As we all know, a Pancoast gives an
N3 with a supraclavicular node, but that is really probably an N1.
What kind of N3 nodes are these?
Dr Weder. Thank you for asking this question because this ex-
plains why we included N3 disease. As you know, the TNM staging
system has its limitations, and N3 disease is not always N3 disease,
N2 disease is not N2 disease. As you pointed out, in a centrally lo-
cated tumor and a positive node adjacent to the tumor it is N2 or N3.
By its biological behavior, it is probably most likely an N1 disease.
You mentioned the Pancoast situation, where the supraclavicular
lymph nodes are also not considered N3 but N1 disease.
Then there is another group of N3 disease that we have included,
and this started when we had PET/CT scan available. We found iso-
lated lymph nodes in the contralateral site at 1 station, and we asked
ourselves the question, why do we have to exclude them? If they
would be 5 mm closer to the ipsilateral site, it would be an N2
and we would do induction therapy. So we performed induction
therapy followed by surgery in a couple of these patients, and we
found long-term survival and even cure, and thereafter we did
a phase II multicenter study including these patients, and this paper
is currently under review for publication.
Dr Cerfolio. You heard yesterday in our breakout session how
the medical oncologists and radiation oncologists want us to use cu-
rative doses of chemoradiotherapy beforehand, and I personally
agree with that and made that cognitive leap almost 10 years ago,
in 2000, and we have written about how it is safe to do a thoracot-
omy and pulmonary resection after 66 or even 70 Gy. You use 45
Gy. Are you going to make that cognitive leap, and do you think
you can do a pneumonectomy after 60 or 66 cGy? Don’t you think
this offers maximal medical therapy in case surgery is not offered
and thus avoids gaps and delays in the delivered amount of radia-
tion dose before surgery?
Dr Weder. The more radiotherapy you apply, the higher risk of
mortality and morbidity. This is clearly documented in the litera-1430 The Journal of Thoracic and Cardiovascular Surture. We have to balance this. How much risk do we want to
take? This is a question that should be addressed by a multicenter
study. We should compare 45 with 60 cGy and then go thereafter
for surgery, because if you achieve good downstaging with 45
cGy and have resectability, then it favors this approach, because
you have definitely less morbidity and mortality. So I favor a mul-
ticenter randomized study.
Dr Cerfolio. It sounds like you are not willing to make that leap,
but we will talk about it later. My third and final question is the re-
assessment of N2 nodes. Most of us would say if those N2 nodes
are still positive, we certainly wouldn’t do a pneumonectomy,
maybe a lobectomy in a young patient, but not a pneumonectomy.
So tell me how you reassess the mediastinum (repeat endobronchial
ultrasound, repeat endobronchial ultrasound-guided fine-needle as-
piration, repeat mediastinoscopy), and when do you not believe the
results based on the PET’s percentage change in the maximum stan-
dardized uptake value and then do a more invasive biopsy, such as
video-assisted thoracic surgery in the opposite chest, where the le-
sions are located?
Dr Weder. The reassessment is sometimes easy and sometimes
difficult. I think it is easy for us when there is a good response to
the treatment. We usually do not reassess the mediastinum in patients
with a good response. They go for surgery directly. Those who are
progressive are not candidates. But then there are the ones in between,
and in our study they were reassessed by mediastinoscopy if this
influenced the decision for resection, because at that time EBUS
was not available yet, only maybe the last 1 or 2 years of the study.
DrMark Krasna (Towson, Md). Again, I’d like to focus on the
group that received chemotherapy with radiation therapy, and I
think that subgroup is of greatest interest to us. Tom Treasure’s re-
cent article in the European Journal emphasized that we don’t al-
ways have to do a prospective randomized trial to answer an
intuitively correct question. Your institution now is the sixth series
in the thoracic literature, which is large enough for us to analyze re-
sults of pneumonectomy after chemoradiotherapy, and these re-
sults, like the ones from Rush, Alabama, our own in Baltimore,
Ben Daley’s group in Boston, and one from Poland last year, all
show that you can do this treatment approach with less than 26%
mortality and no difference between right and left.
My question to you is very specific regarding a patient who has
N2 disease. If you were to give that patient chemotherapy and radi-
ation therapy up front, as you see that your results of pathologic com-
plete response are better than the rest, why are you persisting in only
giving patients chemotherapy followed by surgery? Why not at least
give all the patients chemotherapy with radiation at 45 cGy or, as
Cerf says, chemotherapy with full-dose radiation at 60 cGy?
Dr Weder. I think scientifically the answer is not clear yet, and
we are currently performing a study randomizing them in chemo-
therapy versus chemoradiotherapy.
DrKrasna.There are no data in the literature to show a pathologic
response rate anything greater than 4% with chemotherapy alone.
Dr Weder. Complete pathologic response is seen in 8% to 13%
after chemotherapy alone. However, we used chemoradiotherapy
in 80% of the patients, which may explain the higher response rate.gery c June 2010
